Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00WBN
|
|||
| Former ID |
DIB008021
|
|||
| Drug Name |
ALV-003
|
|||
| Synonyms |
Gluten-detoxifying protease (celiac sprue), Alvine Pharmaceuticals; Glutamine-specific cysteine protease (EP-B2) + proline-specific prolyl endopeptidase (PEP) (celiac disease), Alvine
Click to Show/Hide
|
|||
| Indication | Coeliac disease [ICD-11: DA95; ICD-10: K90.0; ICD-9: 579] | Phase 2 | [1] | |
| Company |
Alvine Pharmaceuticals Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prolyl endopeptidase (PREP) | Target Info | Modulator | [2] |
| KEGG Pathway | Renin-angiotensin system | |||
| Panther Pathway | Vasopressin synthesis | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00959114) Safety and Efficacy of ALV003 for the Treatment of Celiac Disease. U.S. National Institutes of Health. | |||
| REF 2 | The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin Immunol. 2010 Mar;134(3):289-95. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.